Progesterone Sensitizes Ovarian Cancer Cells to Paclitaxel by Reshaping Microtubule Chemistry

Ovarian cancer remains one of the most lethal gynecologic malignancies, and a new laboratory study suggests that an unexpected ally may be hiding in one of the body’s oldest hormones. Researchers report that progesterone, the steroid hormone best known for its role in pregnancy, can reprogram the molecular machinery of ovarian cancer cells in a way that makes them markedly more vulnerable to paclitaxel, the taxane chemotherapy that anchors most treatment regimens for the disease. The findings, published in Cancer Reports, point to a hormone-drug interaction that could eventually inform new combination strategies, though the authors are careful to frame the work as early-stage and hypothesis-generating.

The scale of the clinical problem gives the research its urgency. Ovarian cancer is the sixth leading cause of cancer-related death among women in the United States, with roughly 21,000 new diagnoses and nearly 13,000 deaths each year. Because early-stage disease is frequently silent, more than half of patients are discovered only after the tumor has spread across the peritoneal cavity, often accompanied by malignant ascites. Standard care combines cytoreductive surgery with platinum agents, a taxane, and bevacizumab, and many patients initially achieve complete or partial remission. Yet that benefit is typically short-lived: more than half relapse, and the disease ultimately proves fatal for most of them. New therapeutic angles are badly needed.

The Japanese research team, led by Takahiro Koyanagi and Yasushi Saga, focused on a protein family with a double identity. The vasohibins consist of vasohibin-1, an angiogenesis inhibitor produced by vascular endothelial cells, and vasohibin-2, a homolog that tumors themselves secrete to promote new blood vessel growth. The group had previously shown that forcing VASH1 expression suppresses tumor growth and peritoneal dissemination in ovarian cancer models, while VASH2 knockdown or antibody blockade similarly restrains tumor progression. Crucially, VASH2 is barely detectable in normal tissues, and mice engineered to lack it show no obvious abnormalities, making it an attractive drug target with a potentially wide therapeutic window.

What has transformed the field in recent years is the discovery that vasohibins are not merely signaling molecules. They function as tubulin carboxypeptidases, enzymes that clip the terminal tyrosine residue from alpha-tubulin, a chemical modification known as detyrosination that alters microtubule behavior. This matters enormously for oncology because paclitaxel works by binding beta-tubulin, stabilizing microtubules, and freezing their dynamic equilibrium so that dividing cells cannot complete mitosis. The researchers had already shown that ovarian cancer cells with VASH2 knocked out by CRISPR/Cas9 display reduced detyrosinated microtubules and dramatically heightened sensitivity to paclitaxel, hinting that anything which modulates VASH2 activity might tune the cell’s response to the drug.

Progesterone entered the picture through the team’s earlier work on non-genomic hormone signaling. Classically, progesterone diffuses into the nucleus and binds nuclear progesterone receptors, which regulate gene transcription. But a second family of receptors, the membrane progesterone receptors, sits on the cell surface and triggers rapid, non-genomic responses. The two ovarian cancer cell lines used in the study, TU-OS-4 and OVKATE, are progesterone receptor-negative but express membrane progesterone receptors, and the team had previously shown that progesterone can kill these cells quickly through mPR-mediated mechanisms and can enhance sensitivity to SN38, the active metabolite of irinotecan, by suppressing topoisomerase I and inducing ferroptosis.

In the new experiments, the researchers exposed both cell lines to a high concentration of progesterone, 400 micromolar, for just 30 minutes, then measured VASH2 messenger RNA by quantitative reverse transcription PCR. Expression rose significantly in both lines compared with untreated controls. Western blotting told a consistent story at the protein level: detyrosinated alpha-tubulin accumulated in progesterone-treated cells, and cyclin B1, a regulatory protein that rises from the G2 phase into early mitosis and partners with Cdk1 to drive cells through metaphase, appeared in treated cells while remaining nearly absent in controls. Together, the results sketch a picture of progesterone pushing cells toward a state of altered microtubule chemistry and perturbed mitotic progression.

The functional payoff came in the drug sensitivity assays. When cells were pretreated with 100 micromolar progesterone for 30 minutes and then challenged with paclitaxel for 48 hours, the paclitaxel IC50 fell from 35.3 to 19.8 nanomolar in TU-OS-4 cells, a 1.8-fold gain in sensitivity, and from 128.0 to 9.5 nanomolar in OVKATE cells, a striking 13.5-fold gain, with both differences statistically significant at p less than 0.01. Gemcitabine, an antimetabolite that attacks DNA rather than microtubules, showed no such shift in either line, its IC50 remaining essentially unchanged. That selectivity is the strongest clue that the progesterone effect operates specifically through the microtubule pathway that paclitaxel targets.

The authors are candid about what the study does and does not prove. Because the effects appeared within 30 minutes in progesterone receptor-negative cells, they most likely reflect non-genomic signaling through membrane progesterone receptors, but the team did not directly inhibit or knock down those receptors, so mPR dependence remains an inference rather than a demonstration. Likewise, the measurements captured VASH2 mRNA and detyrosinated tubulin, not VASH2 protein abundance or enzymatic activity, so the link between the hormone, the enzyme, and the drug response is an association consistent with causality rather than a proven causal chain. Direct assessment of spindle function and microtubule dynamics was also beyond the scope of the work.

There are other caveats that temper any temptation to celebrate. The progesterone concentrations used far exceed physiological circulating levels; they were chosen because comparable conditions reproducibly triggered early non-genomic responses in previous experiments without nonspecific cytotoxicity, not because they mirror the endocrine environment in a patient’s body. The authors also stress that progesterone biology is highly context-dependent, shaped by receptor expression profiles, tumor subtype, and the hormonal microenvironment, and recent evidence suggests the hormone can exert distinct or even opposing effects depending on cellular context rather than acting uniformly protectively in ovarian cancer. Generalizing these findings across the heterogeneity of real tumors would be premature.

Even so, the study adds an intriguing layer to a research program that has steadily built the case for VASH2 as a therapeutic target, from shRNA knockdowns that suppressed peritoneal dissemination in animal models, to atelocollagen-protected siRNA that inhibited tumor growth in vivo, to a neutralizing anti-VASH2 antibody with efficacy comparable to bevacizumab and no apparent adverse effects in mice. If progesterone can push ovarian cancer cells into a microtubule state that paclitaxel exploits more effectively, a hormonally guided priming strategy could one day widen the therapeutic index of an indispensable drug. Whether VASH2’s roles in angiogenesis and microtubule regulation are independent or interconnected remains an open question, and the authors call for lower concentrations, prolonged exposures, in vivo models, and mechanistic studies to determine whether the promise survives translation. For now, the message is one of cautious excitement: an old hormone, viewed through the lens of modern microtubule biology, may have more to offer ovarian cancer patients than anyone suspected.

Subject of Research: Progesterone effects on vasohibin-2 expression, tubulin detyrosination, and paclitaxel sensitivity in ovarian cancer cells

Article Title: Progesterone Is Associated With Increased Vasohibin‐2 Expression, Tubulin Detyrosination, and Paclitaxel Sensitivity in PR‐Negative Ovarian Cancer Cells

Article References: Koyanagi, T., Saga, Y., Takahashi, Y., Tamura, K., Suizu, E., Yamamoto, K., Taneichi, A., Takei, Y., Mizukami, H., & Fujiwara, H. (2026). Progesterone Is Associated With Increased Vasohibin‐2 Expression, Tubulin Detyrosination, and Paclitaxel Sensitivity in PR ‐Negative Ovarian Cancer Cells. Cancer Reports, 9(9), Article e70681. https://doi.org/10.1002/cnr2.70681

Image Credits: AI Generated

DOI: 10.1002/cnr2.70681

Keywords: ovarian cancer, progesterone, paclitaxel, vasohibin-2, tubulin detyrosination, membrane progesterone receptor, microtubules, chemosensitivity, cyclin B1, angiogenesis, gemcitabine, drug resistance